BR112016009901A8 - uso de citrato férrico - Google Patents

uso de citrato férrico Download PDF

Info

Publication number
BR112016009901A8
BR112016009901A8 BR112016009901A BR112016009901A BR112016009901A8 BR 112016009901 A8 BR112016009901 A8 BR 112016009901A8 BR 112016009901 A BR112016009901 A BR 112016009901A BR 112016009901 A BR112016009901 A BR 112016009901A BR 112016009901 A8 BR112016009901 A8 BR 112016009901A8
Authority
BR
Brazil
Prior art keywords
iron
increase
reduce
levels
need
Prior art date
Application number
BR112016009901A
Other languages
English (en)
Portuguese (pt)
Inventor
Poradosu Enrique
F Oliviero James Iii
Bentsur Ron
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of BR112016009901A8 publication Critical patent/BR112016009901A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112016009901A 2013-11-04 2014-11-03 uso de citrato férrico BR112016009901A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
BR112016009901A8 true BR112016009901A8 (pt) 2020-04-14

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009901A BR112016009901A8 (pt) 2013-11-04 2014-11-03 uso de citrato férrico

Country Status (15)

Country Link
US (3) US20160256486A1 (https=)
EP (2) EP3747432A1 (https=)
JP (3) JP2016535780A (https=)
KR (1) KR102392441B1 (https=)
CN (1) CN105873583A (https=)
AU (1) AU2014341975A1 (https=)
BR (1) BR112016009901A8 (https=)
CA (1) CA2928200A1 (https=)
EA (1) EA201690926A1 (https=)
HK (1) HK1223031A1 (https=)
IL (1) IL245317A0 (https=)
MX (1) MX2016005734A (https=)
SG (1) SG11201603091QA (https=)
TW (2) TW202203910A (https=)
WO (1) WO2015066593A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938585A (zh) 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JP2022505697A (ja) 2018-10-29 2022-01-14 ファーマコスモス ホールディング エー/エス カルボキシマルトース第二鉄による鉄欠乏症の治療
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
CN117999069A (zh) * 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (https=) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
KR20080094013A (ko) * 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
EP2590655B1 (en) * 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
TWI744215B (zh) 2021-11-01
JP2016535780A (ja) 2016-11-17
TW202203910A (zh) 2022-02-01
JP2021073230A (ja) 2021-05-13
SG11201603091QA (en) 2016-05-30
IL245317A0 (en) 2016-06-30
US20160256486A1 (en) 2016-09-08
HK1223031A1 (zh) 2017-07-21
JP6828100B2 (ja) 2021-02-10
MX2016005734A (es) 2016-11-08
AU2014341975A1 (en) 2016-05-19
WO2015066593A1 (en) 2015-05-07
CA2928200A1 (en) 2015-05-07
KR20160096597A (ko) 2016-08-16
EP3065734A1 (en) 2016-09-14
JP2019206562A (ja) 2019-12-05
KR102392441B1 (ko) 2022-05-02
EP3065734A4 (en) 2017-05-17
CN105873583A (zh) 2016-08-17
TW201609088A (zh) 2016-03-16
US20190307791A1 (en) 2019-10-10
US20250360167A1 (en) 2025-11-27
EA201690926A1 (ru) 2016-09-30
EP3747432A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
BR112016009901A8 (pt) uso de citrato férrico
EP4335436A3 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
BR112014007487A2 (pt) peptídeos terapêuticos
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
BR112015021576A2 (pt) peptídeos terapêuticos
BR112017019279A2 (pt) kits e dispositivos descartáveis para redução de oxigênio e métodos de uso dos mesmos
BR112014029752A2 (pt) uso de n-metil-n-acilglucaminas como estabilizadores de frio em soluções de tensoativos
WO2014141152A3 (en) Low concentration antibody formulations
EA201591618A1 (ru) Замещенные имидазопиридазины
BR112014011670A2 (pt) anticorpo anti- adrenomedulina (adm) ou fragmento de anticorpo anti -adm ou uma estrutura anti- adm não-ig para utilização em terapia
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
HK1218553A1 (zh) 抗激活素a化合物对受试者的施用
HK1213767A1 (zh) 使用固定劑量凝血因子的方法
PH12015502163B1 (en) Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
BR112015018549A2 (pt) métodos de tratamento de deficiência de ferro com pirofosfato férrico solúvel
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
EA201600398A1 (ru) Тиенопиримидины в качестве ингибиторов mknk1 и mknk2
EA201990403A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
BR112014007172A2 (pt) aglutinante para a formação de produtos baseados em partículas ou laminados
MX2015001508A (es) El uso de antitrombina en la oxigenacion por membrana extracorporea.
BR112015030202A2 (pt) composições para alvejamento de polpa e uso das mesmas
BR112014009414A2 (pt) uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL